Six-Month Data Show Bifeprunox Maintained Stability Significantly Longer than Placebo and had a Favorable Weight and Lipid Profile Comparable with Placebo
MARIETTA, Ga. and COLLEGEVILLE, Pa., May 22, 2007 - Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), and Lundbeck A/S presented clinical study results on bifeprunox, an investigational treatment for adult patients diagnosed with schizophrenia, today at the 2007 annual meeting of the American Psychiatric Association. New analyses of six-month data in stabilized adult patients with schizophrenia from a double-blind, placebo-controlled study demonstrated that bifeprunox maintained stability vs. placebo and displayed a favorable weight and lipid profile comparable with placebo.
"Schizophrenia is a chronic, lifelong illness, and long-term management of the illness presents many challenges," comments Daniel Casey, M.D., Professor, Psychiatry and Neurology, Oregon Health and Science University. "Clinicians need new treatment options to help patients manage schizophrenia over the long term."
A synopsis of abstracts containing bifeprunox data presented at the meeting follows:
o In analyses of data from one Phase 3, six-month, randomized, double-blind, placebo-controlled study:
* Compared with placebo, bifeprunox significantly prolonged time to deterioration over six months.
* Bifeprunox patients experienced decreases in body weight and body mass index vs. placebo over six months.
* Bifeprunox patients showed favorable effects on total cholesterol, triglycerides, very low-density lipoprotein and low-density lipoprotein, comparable with placebo over a six-month period.
In these analyses, the most common side effects reported with
bifeprunox (incidence of greater than or equal to 5 percent and
twice the placebo rate) included nausea, vomiting, dizziness,
anorexia, akathisia, dyski